{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"5.1"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"1.9","value":"1.8"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG002","lowerLimit":"1.0","upperLimit":"NA","value":"1.8"},{"groupId":"OG003","lowerLimit":"1.7","upperLimit":"2.1","value":"1.8"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG004","lowerLimit":"1.1","upperLimit":"NA","value":"1.7"},{"groupId":"OG005","lowerLimit":"0.9","upperLimit":"15.4","value":"2.9"},{"groupId":"OG006","lowerLimit":"0.3","upperLimit":"24.6","value":"1.4"},{"groupId":"OG007","lowerLimit":"0.3","upperLimit":"2.0","value":"1.5"},{"groupId":"OG008","lowerLimit":"0.4","upperLimit":"5.4","value":"1.6"},{"groupId":"OG009","lowerLimit":"4.4","upperLimit":"15.1","value":"5.2"},{"groupId":"OG010","lowerLimit":"1.4","upperLimit":"5.9","value":"4.6"},{"groupId":"OG011","lowerLimit":"1.2","upperLimit":"8.4","value":"6.9"},{"groupId":"OG012","lowerLimit":"1.9","upperLimit":"16.8","value":"9.4"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG013","lowerLimit":"1.6","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG014","lowerLimit":"0.6","upperLimit":"NA","value":"1.0"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG015","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG016","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG017","lowerLimit":"1.9","upperLimit":"12.7","value":"4.6"},{"groupId":"OG018","lowerLimit":"1.8","upperLimit":"28.0","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"11"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"24"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"4"},{"groupId":"OG017","value":"14"},{"groupId":"OG018","value":"8"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is the time from start of treatment to disease progression or death (due to any cause), whichever occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with solid tumors (ST) received carfilzomib (CFZ) 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG000","title":"P1B ST: CFZ 20 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG001","title":"P1B ST: CFZ 20/27 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG002","title":"P1B ST: CFZ 20/36 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG003","title":"P2 ST: CFZ 20/36 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG004","title":"P1B ST: CFZ 36 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG005","title":"P1B ST: CFZ 45 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG006","title":"P1B ST: CFZ 20/45 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG007","title":"P1B ST: CFZ 20/56 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG008","title":"P1B ST: CFZ 20/70 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG009","title":"P1B MM: CFZ 20/36 mg/m²"},{"description":"Participants with multiple myeloma (MM) received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG010","title":"P1B MM: CFZ 20/45 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG011","title":"P1b MM: CFZ 20/56 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG012","title":"P1B MM: CFZ 20/70 mg/m²"},{"description":"Participants with non-Hodgkin's lymphoma (NHL) received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG013","title":"P1B NHL: CFZ 20/56 mg/m²"},{"description":"Participants with non-Hodgkin's lymphoma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG014","title":"P1B NHL: CFZ 20/70 mg/m²"},{"description":"Participants with Waldenstrom macroglobulinemia (WM) received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG015","title":"P1B WM: CFZ 20/56 mg/m²"},{"description":"Participants with Waldenstrom macroglobulinemia (WM) received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG016","title":"P1B WM: CFZ 20/70 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG017","title":"P1B MM: CFZ 20/45 mg/m² + Dex"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.","id":"OG018","title":"P1B MM: CFZ 20/56 mg/m² + Dex"}],"paramType":"MEDIAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"months"}